ALLMedicine™ Hepatocellular Carcinoma Center
Research & Reviews 60,713 results
https://doi.org/10.1245/s10434-021-09751-z 10.1002/hep.29913 10.1097/01.sla.0000171307.37401.db 10.1002/jhbp.502 10.1067/msy.2003.102 10.1016/S1499-3872(14)60253-8 10.1016/j.surg.2014.05.012 10.1016/j.jamcollsurg.2010.06.005 10.1016/j.surg.2010.10.001 10.1016/j.jamcollsurg.2008.05.024 10.1002/jhbp.769 10.1016/j.hpb.2017.06.003 10.1002/jso.21414 10.1097/SLA.0000000000002486 10.1016/j.surg.2017.08.024 10.1002/bjs.11329 10.1097/SLA.0b013e31825a01f6 10.1016/j.ijsu.2018.02.059 10.1097/SLA.0b013e31815f6e5b 10.1002/bjs.9815 10.1097/SLA.0000000000002981 10.1002/jso.24501 10.1016/j.hpb.2017.11.012 10.1002/bjs.10093 10.1097/00000658-200103000-00012 10.1016/j.jhep.2014.04.032 10.1245/s10434-016-5174-7 10.1097/SLA.0000000000000710 10.1097/SLA.0000000000003358 10.1002/cncr.20892
Annals of Surgical Oncology; Orimo T, Kamiyama T et. al.
Mar 1st, 2021 - In terms of anatomical liver sectionectomy approaches, both a central hepatectomy (CH) and major hepatectomy (MH) are feasible options for a centrally located hepatocellular carcinoma (HCC). We retrospectively reviewed the surgical outcomes of cen...
https://doi.org/10.1007/s11523-021-00797-3 10.1056/NEJMoa0708857 10.1016/S1470-2045(08)70285-7 10.1016/S0140-6736(18)30207-1 10.1056/NEJMoa1915745 10.1200/JCO.2012.47.3009 10.1001/jama.2014.7189 10.1016/S1470-2045(15)00050-9 10.1093/annonc/mdy101 10.1016/S1470-2045(18)30146-3 10.1016/S0140-6736(16)32453-9 10.1056/NEJMoa1717002 10.1016/S1470-2045(18)30937-9 10.1111/liv.14496 10.1111/liv.14573 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B 10.1016/j.jhep.2018.04.010 10.1200/JCO.2020.38.4_suppl.499 10.1200/JCO.2020.38.15_suppl.e16680 10.1080/14737140.2020.1712198 10.1038/s41416-019-0488-4 10.1111/liv.14270 10.1200/JCO.2014.57.9151 10.1159/000502714 10.1007/s11523-020-00757-3 10.1155/2018/9095275 10.18632/oncotarget.11565 10.1016/j.jhep.2017.06.026
Targeted Oncology; Bang Y, Yoo C et. al.
Mar 1st, 2021 - Regorafenib has been shown to improve clinical outcomes compared to placebo, becoming a standard second-line therapy for sorafenib-progressed and -tolerated hepatocellular carcinoma (HCC) patients. We performed a multicentre, retrospective study i...
https://doi.org/10.1007/s10637-021-01090-w 10.1056/NEJMoa0708857 10.1016/S1470-2045(08)70285-7 10.1056/NEJMoa1915745 10.1056/NEJMoa1717002 10.1016/S1470-2045(18)30937-9 10.3322/caac.21551 10.1002/ijc.29210 10.1056/NEJMoa1712126 10.1056/NEJMoa1816714 10.1158/1078-0432.CCR-06-0489 10.1038/nrc2502 10.1007/s10555-007-9065-z 10.1093/jnci/93.4.266 10.1038/nrc1893 10.1021/jm701028q 10.1186/s40880-018-0285-0 10.1002/cam4.599 10.1200/JCO.2014.55.7504 10.1200/JCO.2013.54.3660 10.1159/000327739 10.1158/1078-0432.CCR-11-1980 10.1080/01621459.1958.10501452 10.1016/j.cmet.2012.10.017 10.1016/j.freeradbiomed.2012.05.006 10.1186/2049-3002-1-8 10.1128/MCB.24.7.2875-2889.2004 10.1111/j.1582-4934.2011.01337.x 10.1038/nrc3064 10.1016/j.pharmthera.2016.04.009 10.1200/JCO.2009.27.4449 10.1200/JCO.2013.51.4265 10.1016/S1470-2045(17)30381-9 10.1158/1078-0432.CCR-10-3425 10.1007/s00280-017-3256-2 10.1093/neuonc/nou237.12 10.1056/NEJMoa1816047 10.1016/S1470-2045(19)30735-1
Investigational New Drugs; Tran NH, Foster NR et. al.
Mar 1st, 2021 - Background Sorafenib (Sor) remains a first-line option for hepatocellular carcinoma (HCC) or refractory renal cell carcinomas (RCC). PLC/PRF/5 HCC model showed upregulation of hypoxia with enhanced efficacy when Sor is combined with hypoxia-activa...
https://doi.org/10.1016/j.jvir.2020.12.023
Journal of Vascular and Interventional Radiology : JVIR; Villalobos A, Cheng B et. al.
Mar 1st, 2021 - To quantify the relationship of the tumor-to-normal ratio (TNR) attained from the technetium-99m macroaggregated albumin (MAA) and posttreatment yttrium-90 bremsstrahlung (Y90-Brem) single-photon emission computerized tomography (SPECT)/computer t...
https://doi.org/10.12659/AJCR.928801
The American Journal of Case Reports; Umemura A, Nitta H et. al.
Mar 1st, 2021 - BACKGROUND Extrahepatic portal vein obstruction (EHPVO) is one of the most important diseases that causes pre-hepatic portal hypertension, and EHPVO sometimes develops cavernous transformation to maintain hepatopetal flow. In this report, we descr...
Guidelines 121 results
https://doi.org/10.1053/j.gastro.2020.11.051
Gastroenterology Younossi ZM, Corey KE et. al.
Dec 11th, 2020 - Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with global public health impact affecting more than 25% of the global population. NAFLD is associated with significant morbidity and mortality from cirrhosis, h...
https://doi.org/10.1016/j.aohep.2020.09.006
Annals of Hepatology; Arab JP, Dirchwolf M et. al.
Oct 8th, 2020 - Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20-30% of the general population. Furthermore, its prevalence is predicted to increase ex...
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200231/full/
Jul 1st, 2020 - Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506).
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200179/full/
May 28th, 2020 - Donafenib significantly improved overall survival (OS) rates compared with sorafenib in patients with hepatocellular carcinoma (HCC) and did so with favorable safety and tolerability, according to a new study (Abstract 4506).
https://doi.org/10.1016/j.annonc.2019.12.001
Annals of Oncology : Official Journal of the European Soc... Chen LT, Martinelli E et. al.
Feb 18th, 2020 - The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, tre...
Drugs 17 results see all →
Clinicaltrials.gov 61,857 results
https://doi.org/10.1245/s10434-021-09751-z 10.1002/hep.29913 10.1097/01.sla.0000171307.37401.db 10.1002/jhbp.502 10.1067/msy.2003.102 10.1016/S1499-3872(14)60253-8 10.1016/j.surg.2014.05.012 10.1016/j.jamcollsurg.2010.06.005 10.1016/j.surg.2010.10.001 10.1016/j.jamcollsurg.2008.05.024 10.1002/jhbp.769 10.1016/j.hpb.2017.06.003 10.1002/jso.21414 10.1097/SLA.0000000000002486 10.1016/j.surg.2017.08.024 10.1002/bjs.11329 10.1097/SLA.0b013e31825a01f6 10.1016/j.ijsu.2018.02.059 10.1097/SLA.0b013e31815f6e5b 10.1002/bjs.9815 10.1097/SLA.0000000000002981 10.1002/jso.24501 10.1016/j.hpb.2017.11.012 10.1002/bjs.10093 10.1097/00000658-200103000-00012 10.1016/j.jhep.2014.04.032 10.1245/s10434-016-5174-7 10.1097/SLA.0000000000000710 10.1097/SLA.0000000000003358 10.1002/cncr.20892
Annals of Surgical Oncology; Orimo T, Kamiyama T et. al.
Mar 1st, 2021 - In terms of anatomical liver sectionectomy approaches, both a central hepatectomy (CH) and major hepatectomy (MH) are feasible options for a centrally located hepatocellular carcinoma (HCC). We retrospectively reviewed the surgical outcomes of cen...
https://doi.org/10.1007/s11523-021-00797-3 10.1056/NEJMoa0708857 10.1016/S1470-2045(08)70285-7 10.1016/S0140-6736(18)30207-1 10.1056/NEJMoa1915745 10.1200/JCO.2012.47.3009 10.1001/jama.2014.7189 10.1016/S1470-2045(15)00050-9 10.1093/annonc/mdy101 10.1016/S1470-2045(18)30146-3 10.1016/S0140-6736(16)32453-9 10.1056/NEJMoa1717002 10.1016/S1470-2045(18)30937-9 10.1111/liv.14496 10.1111/liv.14573 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B 10.1016/j.jhep.2018.04.010 10.1200/JCO.2020.38.4_suppl.499 10.1200/JCO.2020.38.15_suppl.e16680 10.1080/14737140.2020.1712198 10.1038/s41416-019-0488-4 10.1111/liv.14270 10.1200/JCO.2014.57.9151 10.1159/000502714 10.1007/s11523-020-00757-3 10.1155/2018/9095275 10.18632/oncotarget.11565 10.1016/j.jhep.2017.06.026
Targeted Oncology; Bang Y, Yoo C et. al.
Mar 1st, 2021 - Regorafenib has been shown to improve clinical outcomes compared to placebo, becoming a standard second-line therapy for sorafenib-progressed and -tolerated hepatocellular carcinoma (HCC) patients. We performed a multicentre, retrospective study i...
https://doi.org/10.1007/s10637-021-01090-w 10.1056/NEJMoa0708857 10.1016/S1470-2045(08)70285-7 10.1056/NEJMoa1915745 10.1056/NEJMoa1717002 10.1016/S1470-2045(18)30937-9 10.3322/caac.21551 10.1002/ijc.29210 10.1056/NEJMoa1712126 10.1056/NEJMoa1816714 10.1158/1078-0432.CCR-06-0489 10.1038/nrc2502 10.1007/s10555-007-9065-z 10.1093/jnci/93.4.266 10.1038/nrc1893 10.1021/jm701028q 10.1186/s40880-018-0285-0 10.1002/cam4.599 10.1200/JCO.2014.55.7504 10.1200/JCO.2013.54.3660 10.1159/000327739 10.1158/1078-0432.CCR-11-1980 10.1080/01621459.1958.10501452 10.1016/j.cmet.2012.10.017 10.1016/j.freeradbiomed.2012.05.006 10.1186/2049-3002-1-8 10.1128/MCB.24.7.2875-2889.2004 10.1111/j.1582-4934.2011.01337.x 10.1038/nrc3064 10.1016/j.pharmthera.2016.04.009 10.1200/JCO.2009.27.4449 10.1200/JCO.2013.51.4265 10.1016/S1470-2045(17)30381-9 10.1158/1078-0432.CCR-10-3425 10.1007/s00280-017-3256-2 10.1093/neuonc/nou237.12 10.1056/NEJMoa1816047 10.1016/S1470-2045(19)30735-1
Investigational New Drugs; Tran NH, Foster NR et. al.
Mar 1st, 2021 - Background Sorafenib (Sor) remains a first-line option for hepatocellular carcinoma (HCC) or refractory renal cell carcinomas (RCC). PLC/PRF/5 HCC model showed upregulation of hypoxia with enhanced efficacy when Sor is combined with hypoxia-activa...
https://doi.org/10.1016/j.jvir.2020.12.023
Journal of Vascular and Interventional Radiology : JVIR; Villalobos A, Cheng B et. al.
Mar 1st, 2021 - To quantify the relationship of the tumor-to-normal ratio (TNR) attained from the technetium-99m macroaggregated albumin (MAA) and posttreatment yttrium-90 bremsstrahlung (Y90-Brem) single-photon emission computerized tomography (SPECT)/computer t...
https://doi.org/10.12659/AJCR.928801
The American Journal of Case Reports; Umemura A, Nitta H et. al.
Mar 1st, 2021 - BACKGROUND Extrahepatic portal vein obstruction (EHPVO) is one of the most important diseases that causes pre-hepatic portal hypertension, and EHPVO sometimes develops cavernous transformation to maintain hepatopetal flow. In this report, we descr...
News 1,147 results
https://www.medscape.com/viewarticle/946306
Feb 22nd, 2021 - New guidelines from the American Society of Clinical Oncology were released to address the treatment of advanced hepatocellular carcinoma (HCC). An unprecedented number of new agents have been approved for systemic therapy of HCC in recent years, ...
https://www.medscape.com/viewarticle/945041
Jan 31st, 2021 - Combining transcatheter arterial chemoembolization (TACE) therapy with sorafenib improved progression-free survival (PFS), but not overall survival (OS), when compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC), f...
https://www.medscape.com/viewarticle/945046
Jan 31st, 2021 - Long-term follow-up data show a continued benefit for patients with advanced hepatocellular carcinoma (HCC) treated with nivolumab and ipilimumab after disease progression on sorafenib, according to investigators from the Checkmate 040 trial. At a...
https://www.medscape.com/viewarticle/942681
Dec 15th, 2020 - NEW YORK (Reuters Health) - The U.S. Preventive Services Task Force (USPSTF) continues to recommend screening for hepatitis B virus (HBV) in nonpregnant adolescents and adults at increased risk for HBV infection, concluding with "moderate certaint...
https://www.medscape.com/viewarticle/941615
Nov 25th, 2020 - NEW YORK (Reuters Health) - The burden of hepatocellular carcinoma (HCC) appears likely to move from patients who currently have hepatitis C virus (HCV) infection to those who have previously been cured, a new modeling study suggests. "The new hep...
